Stocks and Investing Stocks and Investing
Mon, October 24, 2022

Jessica Fye Maintained (BMRN) at Buy with Decreased Target to $112 on, Oct 24th, 2022


Published on 2024-10-27 23:35:18 - WOPRAI, Jessica Fye
  Print publication without navigation


Jessica Fye of JP Morgan, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Decreased Target from $140 to $112 on, Oct 24th, 2022.

Jessica has made no other calls on BMRN in the last 4 months.



There are 6 other peers that have a rating on BMRN. Out of the 6 peers that are also analyzing BMRN, 1 agrees with Jessica's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Luca Issi of "RBC Capital" Maintained at Hold with Increased Target to $95 on, Thursday, October 13th, 2022


These are the ratings of the 5 analyists that currently disagree with Jessica


  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $111 on, Thursday, October 13th, 2022
  • Christopher Raymond of "Piper Sandler" Maintained at Buy with Increased Target to $128 on, Tuesday, August 9th, 2022
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $125 on, Thursday, August 4th, 2022
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $122 on, Thursday, August 4th, 2022
  • Olivia Brayer of "Cantor Fitzgerald" Initiated at Buy and Held Target at $110 on, Wednesday, July 13th, 2022
Contributing Sources